Effects of liraglutide on the expression of local renin-angiotensin system, transforming growth factor-pi and collagen type III in pulmonary tissue of diabetic rats

National Medical Journal of China

Volumn 94, Issue 6, 2014, Pages 459-463

  Zhao, Wei ^a   Chen, Guangmin ^b   Sun, Bei ^b   Zheng, Xiao ^a   Wu, Qi ^b   Zhang, Hong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Diabetes mellitus; Liraglutide; Lung; Renin angiotensin system; Transforming growth factor beta 1

Indexed keywords

COLLAGEN TYPE 3; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; RAS PROTEIN; STREPTOZOCIN; SUGAR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIABETES MELLITUS; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL RAT; EXPLORATORY RESEARCH; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIPID DIET; LOW DRUG DOSE; LUNG PARENCHYMA; MALE; NONHUMAN; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WESTERN BLOTTING;

EID: 84898860284     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2014.06.016     Document Type: Article

References (14)

1. de Gasparo M, Catt K J, Inagami T, et al. International union of pharmacology. X X III. The angiotensin II receptors [J]. Pharmacol Rev, 2000, 52: 415-472.
2. Koibuchi Y, Lee W S, Gibbons G H, et al. Role of transforming growth factor-bete 1 in the cellular growth response to angiotensin E[J]. Hypertension, 1993, 21: 1046-1050.
3. Enomoto T, Usuki J, Azuma A, et al. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis [J]. Chest, 2003, 123: 2007-2011.
4. 2008, 39: 910-914.
5. 2011, 42: 226-231.
6. Samson S L, Sathyanarayana P, Jogi M, et al. Exenatide decreases hepatic fibro- blast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomized controlled trial[J]. Diabetologia, 2011, 54: 3093-3100.
7. Tang-Christensen M, Vrang N, Larsen P L. Glucagon-like peptide 1 (7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment[J]. Diabetea, 1998, 47: 530-537.
8. Skov J, Dejgaard A, Frokiaer J, et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men [J]. J Clin Endocrinol Metab, 2013, 98: E664-E671.
9. Ban K, Noyan-Ashraf M H, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways [J]. Circulation, 2008, 117: 2340-2350.
10. Parsons K K, Coffman T M. The rennin-angiotensin system; it's all in your head [J]. J Clin Invest, 2007, 117: 873-876.
11. Kawasaki Y, Harashima S, Sasaki M, et al. Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38 phosphorylation [J]. Horm Metab Res, 2010, 42: 311-317.
12. Liu X H, Wang Y P, Wang L X, et al. Exendin-4 protects murine MIN6 pancreatic beta-cells from interleukin-1 beta-induced apoptosis via the NF-kappaB pathway [J]. J Endocrinol Invest, 2013, 36, 803-811.
13. Ishibashi Y, Nishino Y, Matsui T, et al. Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level [J]. Metabolism, 2011, 60: 1271-1277.
14. Srinivasan K, Viswanad B, Asrat L, et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacol-ogical screening [J]. Pharmacol Res, 2005, 52: 313-320.